Raising awareness of the importance of funding for tuberculosis small-molecule research

Drug Discovery Today

Volumn 22, Issue 3, 2017, Pages 487-491

  Riccardi, Giovanna ^a   Old, Iain G ^b   Ekins, Sean ^c,d  

^a UNIVERSITY OF PAVIA   (Italy)

^b EPFL   (Switzerland)

^c Collaborative Drug Discovery Inc ^*  (United States)

^d Collaborations in Chemistry ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; TUBERCULOSTATIC AGENT;

AWARENESS; DRUG DEVELOPMENT; DRUG RESEARCH; EUROPEAN UNION; FUNDING; HUMAN; LOBBYING; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PUBLIC-PRIVATE PARTNERSHIP; SHORT SURVEY; TUBERCULOSIS; ECONOMICS; EUROPE; FINANCIAL MANAGEMENT; MEDICAL RESEARCH;

ANTITUBERCULAR AGENTS; BIOMEDICAL RESEARCH; EUROPE; RESEARCH SUPPORT AS TOPIC; TUBERCULOSIS;

EID: 85008622616     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2016.09.012     Document Type: Short Survey

References (30)

1. 1 Lonnroth, K., et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur. Respir. J. 45 (2015), 928–952.
2. 2 WHO, Global Tuberculosis Report. 2013, World Health Organization.
3. 3 WHO, Global Tuberculosis Report 2014., 2014, WHO.
4. 4 Jakab, Z., et al. Consolidated action plan to prevent and combat multidrug- and extensively drug-resistant tuberculosis in the WHO European Region 2011–2015: cost-effectiveness analysis. Tuberculosis 95:Suppl. 1 (2015), S212–S216.
5. 5 Zignol, M., et al. Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data. Drug Resist. Updates 16 (2013), 108–115.
6. 6 Velayati, A.A., et al. The totally drug resistant tuberculosos (TDR-TB). Int. J. Clin. Exp. Med. 6 (2013), 307–309.
7. 7 Abubakar, I., et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect. Dis. 13 (2013), 529–539.
8. 8 Dheda, K., Migliori, G.B., The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue?. Lancet 379 (2012), 773–775.
9. 9 Gothi, D., Joshi, J.M., Resistant TB: newer drugs and community approach. Recent Pat. Antiinfect. Drug Discov. 6 (2011), 27–37.
10. 10 Udwadia, Z.F., et al. Totally drug-resistant tuberculosis in India. Clin. Infect. Dis. 54 (2012), 579–581.
11. 11 Velayati, A.A., et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest J. 136 (2009), 420–425.
12. 12 WHO, A Global Action Framework for TB Research. 2015, WHO.
13. 13 Stop TB Partnership, The Paradigm Shift 2016–2020 Global Plan to End TB, Stop TB Partnership. 2015.
14. 14 Fang, F.C., Casadevall, A., Research funding: the case for a modified lottery. MBio, 7, 2016 e00422–e00416.
15. 15 Lienhardt, C., Fundamental research is the key to eliminating TB. Nature, 507, 2014, 401.
16. 16 Nathan, C., Cooperative development of antimicrobials: looking back to look ahead. Nat. Rev. Microbiol. 13 (2015), 651–657.
17. 17 Paul, S.M., et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9 (2010), 203–214.
18. 18 European Commission, World Tuberculosis Day 2015: EU Research to Fight Tuberculosis. 2015, European Commission.
19. 19 European Commission, World Tuberculosis Day 2015: Together We Must Address the Social Inequalities that Allow Tuberculosis to Spread. 2015, European Commission.
20. 20 Ekins, S., Wood, J., Incentives for starting small companies focused on rare and neglected diseases. Pharm. Res. 33 (2016), 809–815.
21. 21 Sachs-Barrable, K., et al. The use of the United States FDA programs as a strategy to advance the development of drug products for neglected tropical diseases. Drug Dev. Ind. Pharm. 40 (2014), 1429–1434.
22. 22 Anon, Rare Pediatric Disease Priority Review Voucher Program. 2014, FDA.
23. 23 Anon, Accelerated Approval. 2014, FDA.
24. 24 Miyamoto, B.E., Kakkis, E.D., The potential investment impact of improved access to accelerated approval on the development of treatments for low prevalence rare diseases. Orphanet. J. Rare Dis., 6, 2011, 49.
25. 25 Siva, N., Crowdfunding for medical research picks up pace. Lancet 384 (2014), 1085–1086.
26. 26 Dahlhausen, K., et al. Crowdfunding campaigns help researchers launch projects and generate outreach. J. Microbiol. Biol. Educ. 17 (2016), 32–37.
27. 27 Larkin, M., How to Use Crowdfunding to Support your Research. 2013, Elsevier.
28. 28 Vachelard, J., et al. A guide to scientific crowdfunding. PLoS Biol., 14, 2016, e1002373.
29. 29 Perlstein, E.O., Anatomy of the Crowd4Discovery crowdfunding campaign. Springerplus, 2, 2013, 560.
30. 30 Pollastri, M.P., Finding new collaboration models for enabling neglected tropical disease drug discovery. PLoS Negl. Trop. Dis., 8, 2014, e2866.